2007, Number 3
<< Back Next >>
Rev Invest Clin 2007; 59 (3)
Abdomen agudo no quirúrgico como presentación clínica de Fiebre Mediterránea Familiar
Halabe-Cherem J, Rábago-Arredondo J
Language: Spanish
References: 22
Page: 212-218
PDF size: 79.23 Kb.
Text Extraction
No abstract
REFERENCES
Cherem JH, Hummel HN, Padilla GF. Familial Mediterranean fever in Mexico City: 10-year follow-up. Archives of Internal Medicine 1994; 154(12): 1411, 4.
Halabe J, Islas S, Mercado M. Fiebre Mediterránea familiar en la ciudad de México. Rev Invest Clin 1986; 38: 389-93.
Ozdemir A. Familial mediterranean fever among the turkish people. Am J Gastroenterol 1969(51): 311-6.
Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Bailliere’s Best Practice & Research 2000; 14(3): 477-98.
Avila R, Halabe J, Lifshitz A. Patogenia de la fiebre mediterránea familiar. Rev Med IMSS 1987; (25): 321-9.
The International FMF Consortium. Cell 1997; (17): 25-31.
The French FMF Consortium. Nat Genet 1997; (17): 25-31.
Halabe J, Nellen H, Flores G. Familial mediterranean fever and primary antiphospholipid, a rare association. Angiology 1995; (46): 859-61.
Disdier P. Familial mediterranean fever crisis and lupus anticoagulant. Lancet 1996; (348): 1321-2.
Cook G. Familial mediterranean fever: underlying defect clearer, but diagnosis problems persist. Lancet 1996; (1996): 1779-80.
Balow J. A high resolution genetic map of the familial mediterranean fever. Genomics 1997; (44): 280-91.
Rogers D. Familial mediterranean fever. Am J Med Genet 1989; (34): 168-72.
Babior B, Matzner Y. The familial mediterranean fever genecloned at last. N Engl J Med 1997; (337): 1548-9.
Schaner PE, Gumucio DL. Familial Mediterranean fever in the post-genomic era: how an ancient disease is providing new insights into inflammatory pathways. Current Drug Targets 2005; 4(1): 67-76.
Masumoto J, Dowds TA, Schaner P, et al. ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. Biochemical and Biophysical Research Communications 2003; 303(1): 69-73.
Koklu S, Ozturk MA, Balci M, Yuksel O, Ertenli I, Kiraz S. Interferon- gamma levels in familial Mediterranean fever. Joint Bone Spine 2005; 72(1): 38-40.
Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002; 10(2): 145-9.
Halabe J, Islas S, Lifshitz A. Persistent fever as the only symptom of familial mediterranean fever. Archives of Internal Medicine 1990; (150): 1347.
Pras E. Familial mediterranean fever. N Engl J Med 1992; 326: 1509-13.
Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43(2): 227-53.
Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Seminars in Arthritis and Rheumatism 1996; 26(3): 612-27.
Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974; 291(18): 932-4.